AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 152 filers reported holding AERIE PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $176,000 | -40.1% | 11,013 | -33.2% | 0.02% | -44.4% |
| Q1 2021 | $294,000 | +90.9% | 16,476 | +44.9% | 0.03% | +68.8% |
| Q4 2020 | $154,000 | -61.7% | 11,373 | -31.6% | 0.02% | -33.3% |
| Q4 2019 | $402,000 | -9.3% | 16,626 | +10.8% | 0.02% | -40.0% |
| Q2 2019 | $443,000 | +21.4% | 15,005 | +177.8% | 0.04% | +60.0% |
| Q2 2018 | $365,000 | -77.2% | 5,401 | -81.7% | 0.02% | -77.7% |
| Q1 2018 | $1,601,000 | +553.5% | 29,516 | +621.0% | 0.11% | +314.8% |
| Q4 2017 | $245,000 | -39.5% | 4,094 | -46.8% | 0.03% | -75.7% |
| Q2 2017 | $405,000 | +1.2% | 7,700 | -27.1% | 0.11% | +76.2% |
| Q4 2016 | $400,000 | +56.9% | 10,566 | +56.6% | 0.06% | +10.5% |
| Q3 2016 | $255,000 | -54.5% | 6,745 | -78.6% | 0.06% | +18.8% |
| Q3 2015 | $560,000 | -11.0% | 31,570 | +57.1% | 0.05% | -25.0% |
| Q1 2015 | $629,000 | – | 20,100 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
| DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
| NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
| HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
| Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
| Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
| PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
| Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |